

**Oxford BioDynamics Plc**  
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

**Result of AGM**

**28 March 2025** - Oxford BioDynamics Plc (AIM: OBD, the "Company"), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that all resolutions proposed at the Company's Annual General Meeting, held earlier today, were duly passed.

**For further details please contact:**

**Oxford BioDynamics Plc** +44 (0)1865 518910  
Iain Ross, Executive Chairman  
Paul Stockdale, CFO

**Shore Capital - Nominated Adviser and Broker** +44 (0)20 7408 4090  
Advisory: Stephane Auton / Lucy Bowden  
Broking: Fiona Conroy

**WG Partners - Joint Broker** +44 (0)20 3705 9330  
David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby

**OAK Securities - Joint Broker** +44 (0)20 3973 3678  
Jerry Keen / Henry Clarke / Damion Carruel

**Camarco - Financial PR** +44 (0)20 3757 4980  
Marc Cohen / Tilly Butcher / Fergus Young  
OBDFinancial@camarco.co.uk

**Notes for Editors**

**About Oxford BioDynamics Plc**

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening test) and [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com), X (@OxBioDynamics) or [LinkedIn](#).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGUWORRVRUOUAR